Rare diseases
Investigational molecules
Locations
Calle De San Antonio Maria Claret 167, 08025 Barcelona, Spain
Hospital De La Santa Creu I Sant Pau in Barcelona, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Dementia Alzheimer's type, Acute myeloid leukaemia, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.
The Hospital De La Santa Creu I Sant Pau conducts cutting‑edge research on neoplasms, focusing on solid tumors and hematologic malignancies across the Barcelona region.
A total of 13 clinical trials involve 186 investigators, advancing therapeutic options for cancer patients.
Within the department of Neurology, the site explores treatments for neurodegenerative and headache disorders, aiming to improve quality of life for affected individuals.
Ongoing studies leverage the expertise of 186 investigators to evaluate efficacy and safety in the nervous system field.
Research in immune system diseases targets autoimmune skin conditions, employing innovative immunomodulatory approaches to reduce disease burden.
The department’s 13 trials aim to expand therapeutic options for patients with challenging immune‑mediated disorders.
The site’s work on respiratory tract diseases integrates oncology and pulmonary health, seeking to improve outcomes for lung‑related malignancies.
Clinical investigations combine oncology expertise with respiratory assessments to refine treatment strategies.
Studies in digestive system diseases concentrate on colorectal cancer, exploring targeted regimens that enable curative surgical interventions.
These trials contribute to multidisciplinary care pathways for patients with gastrointestinal malignancies.
The department supports investigations into congenital and hereditary conditions, emphasizing early detection and genetic counseling to guide preventive strategies.
Collaborative efforts with genetics specialists aim to integrate precision medicine from birth onward.
Research on circulatory and respiratory physiological phenomena underpins many therapeutic trials, providing biomarkers that inform treatment response.
These physiological insights enhance the safety and effectiveness of interventions across multiple disease areas.
Clinical trials currently enrolling participants at this site.
Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity
SpainEfficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis
SpainStudy of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo
SpainA Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis
SpainPhase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs
SpainA Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
SpainPhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
SpainLong-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
SpainBI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus
SpainA study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer
SpainStudy of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
SpainA Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
SpainMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
